As Chief Economist at CSL Limited (from 2004 to 2009), Sam worked on a broad range of economic, commercial and strategic issues .
Strategy: developing strategy for CSL in the international blood therapeutic products and pharmaceutical markets, assess future avenues for growth and development at CSL, and understand the impact of global and local trends on business performance; including assessment of M&A opportunities.
Public policy: preparing submissions to governments, and presenting CSL’s positions to government, media and other interested parties. Support for the CEO on public policy positions.
Health-economic analysis: pharmacoeconomic and related analysis in relevant business areas including influenza vaccine, enhanced influenza vaccine, HPV vaccination (Gardasil), blood and plasma products. Econometric analysis of plasma donor behaviour in different locations.
Economic analysis: market characteristics, pricing, M&A, financial performance and competition issues.
Internal education and executive support: part of team of senior managers speaking to Executive and Global Leadership Programs. Responsible for communicating strategy at internal forums.
Support for internal programs across the group: projects included assessment of cost allocations into products, analysis of donor behaviour, optimisation of plasma donation centres, assessment of viral infection epidemiology and end-product safety.
Negotiation: twice member of the CSL negotiation team for the Australian Fractionation Agreement with the National Blood Authority.